US4956453A
(en)
*
|
1985-12-06 |
1990-09-11 |
Cetus Corporation |
Anti-human ovarian cancer immunotoxins and methods of use thereof
|
CA1289880C
(en)
*
|
1985-12-06 |
1991-10-01 |
Jeffrey L. Winkelhake |
Anti-human ovarian cancer immunotoxins and methods of use thereof
|
US4911911A
(en)
*
|
1985-12-20 |
1990-03-27 |
Sanofi |
Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
|
IL80973A
(en)
*
|
1985-12-20 |
1992-08-18 |
Sanofi Sa |
Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
|
US4786592A
(en)
*
|
1986-06-18 |
1988-11-22 |
Scripps Clinic And Research Foundation |
Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
|
US4771128A
(en)
*
|
1986-10-10 |
1988-09-13 |
Cetus Corporation |
Method of purifying toxin conjugates using hydrophobic interaction chromatography
|
US4985541A
(en)
*
|
1987-04-10 |
1991-01-15 |
Zymogenetics, Inc. |
Novel cytotoxic protein
|
NZ225372A
(en)
*
|
1987-07-17 |
1991-04-26 |
Xoma Corp |
Immunotoxin composition comprising purified ricin-a-chain species
|
WO1989004839A1
(en)
*
|
1987-11-24 |
1989-06-01 |
Genetics Institute, Inc. |
Improved ricin molecules and ricin toxin conjugates
|
ATE195142T1
(de)
*
|
1991-02-26 |
2000-08-15 |
Zeneca Ltd |
Fermentationsverfahren zur herstellung von peptiden durch einen wirt
|
USH1985H1
(en)
|
1992-01-09 |
2001-08-07 |
The United States Of America As Represented By The Secretary Of The Navy |
Method for detecting biological toxins
|
US5453271A
(en)
*
|
1993-06-28 |
1995-09-26 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccine against ricin toxin
|
US5437986A
(en)
*
|
1994-06-22 |
1995-08-01 |
Schering Corporation |
Extraction of heterologous insoluble proteins from bacteria
|
WO2000073346A1
(en)
|
1999-05-27 |
2000-12-07 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Immunoconjugates having high binding affinity
|
US6869787B2
(en)
*
|
2002-02-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Army |
Ricin vaccine and methods of making and using thereof
|
JP4813364B2
(ja)
|
2003-11-25 |
2011-11-09 |
アメリカ合衆国 |
突然変異型抗cd22抗体および免疫複合体
|
US8580927B2
(en)
|
2008-01-31 |
2013-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
WO2010045495A2
(en)
|
2008-10-16 |
2010-04-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
EP3135692B8
(en)
|
2010-06-16 |
2019-03-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
PL3434346T3
(pl)
|
2010-07-30 |
2021-04-06 |
Medimmune, Llc |
Oczyszczone aktywne polipeptydy lub immunokoniugaty
|
EP2699603B1
(en)
|
2011-04-19 |
2016-03-02 |
The United States of America As Represented by the Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
EP2753356B1
(en)
|
2011-09-09 |
2021-12-22 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
EP2825557B1
(en)
|
2012-03-16 |
2017-06-28 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Soluble engineered monomeric fc
|
SG11201407972RA
(en)
|
2012-06-01 |
2015-01-29 |
Us Health |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014100443A2
(en)
|
2012-12-20 |
2014-06-26 |
Medimmune, Llc |
Methods of producing immunoconjugates
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
CA2989347A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
CN108779162B
(zh)
|
2015-10-09 |
2021-12-07 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
CA3031559A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
AU2017321894A1
(en)
|
2016-09-02 |
2019-03-14 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duoCARs
|
WO2018119279A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
ES2936803T3
(es)
|
2017-01-09 |
2023-03-22 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
CA3059472A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
EP3661964A1
(en)
|
2017-07-31 |
2020-06-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
EP4279584A3
(en)
|
2017-10-16 |
2024-03-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
CA3086612A1
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
CA3106544A1
(en)
|
2018-08-08 |
2020-02-13 |
Mitchell Ho |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
WO2020061498A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
JP2022513682A
(ja)
|
2018-11-30 |
2022-02-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd38免疫療法によりがんを処置するための組成物および方法
|
US20220064324A1
(en)
|
2019-01-08 |
2022-03-03 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting mesothelin for treating solid tumors
|
CN113784987A
(zh)
|
2019-01-22 |
2021-12-10 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
EP3934668A1
(en)
|
2019-03-06 |
2022-01-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
CN118345101A
(zh)
|
2019-05-30 |
2024-07-16 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
CN114729041A
(zh)
|
2019-10-22 |
2022-07-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|